NR507 Week 2 Discussion: Heart Failure

The disorder chosen is heart failure (HF). Heart failure is a long-lasting, progressive syndrome whereby heart muscle can no longer pump enough blood to supply adequate blood to support metabolic needs of the body. The symptoms include dyspnea, fatigue, and retention of fluid. HF falls into subtypes, according to left ventricular ejection fraction, as heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) (Rosch et al., 2022). The clinical setting has made this condition a significant issue of concern because of its high morbidity, mortality, and quality of life.

Rationale for Selection

Heart failure was selected because it is important in clinical nursing practice, especially in the management of chronic conditions and minimization of avoidable hospital admissions. HF is one of the most frequent reasons that lead to hospitalization in older patients due to its complicated pathophysiology that demands nurses to combine complex interventions, including medication adjustment, patient education, and monitoring of the fluid status.

Through the clinical rotations, I found out that nurses play a central role by preventing the onset of acute decompensation due to timely diagnosis of symptoms and patient empowerment. Also, the increased rates of HF risk factors, including hypertension and diabetes, provoke the necessity of nurses to concentrate on preventing and managing them (Roger, 2021). The cross-section of this condition with comorbidity and social determinants of health is yet another factor that shows its importance to holistic nursing care.

Prevalence, Incidence, and Affected Populations

Heart failure is an issue with approximately 6.2 million and 550,000 new cases every year in the United States (Centers for Disease Control and Prevention, 2024). The age factor is also a key determinant of prevalence whereby adults aged 65 years and above constitute the largest percentage of patients hospitalized due to HF. At younger ages, men have a higher risk of HF than women do, but the prevalence rates between men and women are equal because women live longer.

The incidence of HF among African Americans is more pronounced, and the outcomes are worse partly because of the inequality in healthcare access, hypertension rate, and socioeconomic conditions (Williams et al., 2020). Such comorbidities as hypertension (75 percent of HF patients have it), coronary artery disease, and diabetes mellitus are closely related to the development of HF. The rural population and those with limited access to primary care are also overrepresented and at the time of diagnosis they are almost always at an advanced stage of the disease.

Scholarly Article Selected

            Anker et al. (2021) conducted an article, also known as Empagliflozin in Heart Failure with a Preserved Ejection Fraction, published by the New England Journal of Medicine, in which clinical researchers explored the effectiveness of SGLT2 inhibitors in the treatment of heart failure with preserved ejection fraction (HFpEF). This was a sub study of the EMPEROR-Preserved trial that included 5,988 patients (with HFpEF (ejection fraction >40)) who were randomized to empagliflozin or placebo. Findings showed that the combined risk of heart failure hospitalization or fatality due to cardiovascular reasons was significantly lowered from the empagliflozin group by 21 percent when compared to the placebo.

The authors suggest that SGLT2 inhibitors alleviate systemic inflammation, enhance myocardial energy metabolism, and decrease interstitial fibrosis to cover the main pathophysiological processes in HFpEF, including diastolic dysfunction and systemic vascular stiffness. Other symptoms such as exertional dyspnea and exercise intolerance were also lower in patients who were put on empagliflozin.

This article is central to nursing practice because a paradigm shift in terms of the management of HFpEF is described, which previously did not have effective therapies. Now, nurses need to be aware of the role of SGLT2 inhibitors with their advantages (e.g. fewer hospitalizations) and possible side effects (e.g. genital infections or loss of volume). The research gives significant emphasis on the issue of patient education on medication adherence and monitoring to side effects as well as older adults, especially those with comorbid conditions such as diabetes, who may already have multiple therapies.

Besides, the results highlight the necessity of nurses to promote the revision of the guidelines and equal access to these drugs, particularly in those under-served groups that are disproportionately impacted by HFpEF. With this evidence combined with the practice, nurses may help achieve better quality of life and decreased morbidity among patients with this difficult condition.